ALK and non-small cell lung carcinoma: Therefore, the identification of ALK fusion status in NSCLC patients may need to use orthogonal assays based on multiomics for fusion detection to achieve an accurate molecular diagnosis and ensure the reliability of the targeted drug use indicators.